NCT04671316View on ClinicalTrials.gov

"Bioequivalence Study Between DA-5209 Tab and Lixiana Tab"

PHASE1CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

February 4, 2021

Study Completion Date

February 4, 2021

Conditions
Healthy
Interventions
DRUG

DA-5209 60mg Tab

"single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water"

DRUG

DA-5209 60mg Tab

"single oral administration of 1 tablet of DA-5209 60mg Tab without water"

DRUG

Lixiana 60mg Tab

"single oral administration of 1 tablet of Lixiana 60mg Tab with 150mL water"

Trial Locations (1)

08779

H Plus Yangji Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT04671316 - "Bioequivalence Study Between DA-5209 Tab and Lixiana Tab" | Biotech Hunter | Biotech Hunter